See more : China Man-Made Fiber Corporation (1718.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Oncorus, Inc. (ONCR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Oncorus, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Ares Management Corporation (ARES) Income Statement Analysis – Financial Results
- Kronos Worldwide, Inc. (KRO) Income Statement Analysis – Financial Results
- Akritas S.A. (AKRIT.AT) Income Statement Analysis – Financial Results
- property technologies Inc. (5527.T) Income Statement Analysis – Financial Results
- Hawaiian Electric Company, Inc. PFD C 4.25% (HAWEN) Income Statement Analysis – Financial Results
Oncorus, Inc. (ONCR)
About Oncorus, Inc.
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 54.74M | 44.68M | 27.15M | 24.05M | 12.54M |
| General & Administrative | 21.79M | 20.14M | 10.00M | 7.12M | 6.04M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 21.79M | 20.14M | 10.00M | 7.12M | 6.04M |
| Other Expenses | 0.00 | -9.00K | -11.29M | -47.00K | 304.00K |
| Operating Expenses | 76.54M | 64.82M | 37.15M | 31.17M | 18.58M |
| Cost & Expenses | 76.54M | 64.82M | 37.15M | 31.17M | 18.58M |
| Interest Income | 911.00K | 65.00K | 143.00K | 509.00K | 228.00K |
| Interest Expense | 2.01M | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.12M | 1.95M | 1.37M | 1.07M | 956.00K |
| EBITDA | -75.42M | -62.87M | -37.15M | -30.10M | -17.62M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -76.54M | -64.82M | -37.15M | -31.17M | -18.58M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -885.00K | 56.00K | -11.15M | 462.00K | 532.00K |
| Income Before Tax | -77.42M | -64.76M | -48.30M | -30.70M | -18.05M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 885.00K | -65.00K | -1.52M | -509.00K | 532.00K |
| Net Income | -78.31M | -64.70M | -46.78M | -30.20M | -18.05M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.02 | -2.56 | -7.69 | -2.42 | -1.97 |
| EPS Diluted | -3.02 | -2.56 | -7.69 | -2.42 | -1.97 |
| Weighted Avg Shares Out | 25.92M | 25.32M | 6.08M | 12.50M | 9.16M |
| Weighted Avg Shares Out (Dil) | 25.92M | 25.32M | 6.08M | 12.50M | 9.16M |
Oncorus to Present at the H.C. Wainwright BioConnect Virtual Conference
Oncorus to Present at the Jefferies London Healthcare Conference
Why Did Oncorus Shares Slump To 52-Week Low Today?
Why Oncorus Stock Is Crashing Today
Oncorus, Gaeta Therapeutics Ink Cancer Candidate Licensing Agreement
Wall Street Analysts Predict a 201% Upside in Oncorus, Inc. (ONCR): Here's What You Should Know
Oncorus: Shares Look Cheap As First Oncolytic Viral Therapy Enters Clinic
Oncorus Appoints Eric Rubin, M.D. to its Board of Directors
Oncorus Announces Nomination of its First IV-Administered Synthetic Viral RNA (vRNA) Immunotherapy Product Candidates, ONCR-021 and ONCR-788
Oncorus Inc.: Undervalued Cancer Viral Immunotherapy Opportunity
Source: https://incomestatements.info
Category: Stock Reports